Medscape www.medscape.com

References for:
Visual Function in Patients Treated With the GABAergic Anticonvulsant Drug Tiagabine

[Clin Drug Invest 20(6):393-400, 2000. © 2000 Adis International Limited]

  1. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997 Jan; 314: 180-1
  2. Kälviäinen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999 Sep; 53: 922-6
  3. Wild JM, Martinez C, Reinshagen G, et al. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40 (12): 1784-94
  4. Midelfart A, Midelfart E, Brodtkorb E. Visual field defects in patients taking vigabatrin. Acta Ophthalmol 2000 Sep; 78: 580-4
  5. Nousiainen I, Kälviäinen R, Mäntyjärvi M. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. Ophthalmology 2000 May; 107: 884-8
  6. Krauss G, Johnson M, Miller N. Vigabtrin-associated retinal cone system dysfunction. Electroretinogram and ophthalmologic findings. Neurology 1998 Mar; 50: 614-8
  7. Arndt CF, Derambure P, Defoort-Dhellemmes S, et al. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999 Apr; 52: 1201-5
  8. Leach JP, Brodie MJ. Tiagabine. Lancet 1998 Jan 17; 351: 203-7
  9. Leppik IE, Gram L, Deaton R, et al. Safety of tiagabine: summary of 53 trials. Epilepsy Res 1999; 33: 235-46
  10. Collins SD, Brun S, Kirstein YG, et al. Absence of visual field defects in patients taking tiagabine (Gabitril ® )[abstract]. Epilepsia 1998; 39 Suppl. 6: 146S-7S
  11. Fakhoury TA, Abou-Khalil B, Lavin P, et al. Lack of visual field defects with long-term use of tiagabine [abstract]. Neurology 2000; 54 Suppl. 3: A309
  12. Beran RG, Hung A, Plunkett M, et al. Predictability of visual field defects in patients exposed to GABAergic agents, vigabatrin, or tiagabine [abstract]. Neurology 1999: 52 Suppl. 2: A249
  13. Steinhoff B, Freudenthaler N, Paulus W. The influence of established and new antiepileptic drugs on visual perception II. A controlled study in patients with epilepsy under long-term antiepileptic medication. Epilepsy Res 1997; 29: 49-58
  14. Bayer A, Thiel HJ, Zrenner E, et al. Color vision test for early detection of antiepileptic drug toxicity. Neurology 1997 May; 48: 1394-7
  15. López L, Thomson A, Rabinowicz L. Assessment of colour vision in epileptic patients exposed to single-drug therapy. Eur Neurol 1999; 41: 201-5
  16. Tomson T, Nilsson BY, Levi R. Impaired contrast sensitivity in epileptic patients treated with carbamazepine. Arch Neurol 1988 Aug; 45: 897-900
  17. Nousiainen I, Kälviäinen R, Mäntyjärvi M. Contrast and glare sensitivity in epilepsy patient treated with vigabatrin or carbamazepine monotherapy compared to healthy volunteers. Br J Ophthalmol 2000 Jun; 84 (6): 622-5
  18. Sartucci F, Massetani R, Galli R, et al. Visual contrast sensitivity in carbamazepine-resistant epileptic patients receiving vigabatrin as add-on therapy. J Epilepsy 1997; 10 (1): 7-11
  19. Egge K. The visual field in normal subjects. Acta Ophthalmol 1984; Suppl. 169: 1-64
  20. Ichikawa H, Hukami K, Tanabe S. Standard Pseudo-isochromatic Plates part 2. Tokyo: Igaku-Shoin Ltd, 1983
  21. Farnsworth D. The Farnsworth-Munsell 100-Hue Test. Baltimore: Munsell Color Company, 1957
  22. Kinnear PR. Proposals for scoring and assessing the 100-hue test. Vision Res 1970; 10: 423-33
  23. Smith V, Pokorny J, Pass A. Color-Axis Determination on the Farnsworth-Munsell 100-Hue Test. Am J Ophthalmol 1985 Jul; 100: 176-82
  24. Verriest G, Van Laethem J, Uvijls A. A new assesment of the normal ranges of the Farnsworth-Munsell 100-Hue test scores. Am J Ophthalmol 1982 May; 93 (5): 635-42
  25. Roth A. Metameric matches relevant for assessment of color vision II. Practical apsects. In Verriest G, editor. Colour Vision Deficiences VII. Proceedings of the Seventh Symposium of the International Research Group on Colour Vision Deficiencies; 1984 June 23-25; Geneva, Switzerland. The Hague: W Junk Publishers, 1984: 95-109 (Doc Ophthalmol Proc Ser 39)
  26. Rossillion B, Pelizzone M, Sommerhalder J, et al. Automated Moreland equations on 7 o and 2 o fields. In Drum B, editor. Colour Vision Deficiencies XII. Proceedings of the Twelfth Symposium of the International Research Group on Color Vision Deficiencies; 1993 July 18-22; Tübingen, Germany. Dortdrecht: Kluwer Academic Publisher, 1995: 481-8 (Doc Ophthalmol Proc Ser 57)
  27. Birch J, Chisholm I, Kinnear P, et al. Clinical Testing Methods. In Pokorny J, Smith V, Verriest G, Pinckers A, editors. Congenital and Acquired Color Vision Defects. NewYork: Grune & Stratton, 1979: 83-135
  28. Pelli D, Robson J, Wilkins A. The design of a new letter chart for measuring contrast sensitivity. Clin Vision Sci 1988; 2 (3): 187-99
  29. Rubin G. Reliability and sensitivity of clinical contrast sensitivity tests. Clin Vision Sci 1988; 2 (3): 169-77
  30. Mäntyjärvi M, Laitinen T. Normal values of the Pelli-Robson contrast sensitivity test. J Cataract Refract Surg. In press